The epithelial polarity regulator LGALS9/galectin- 9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux

Autophagy

Volumn 11, Issue 8, 2015, Pages 1373-1388

  Wiersma, Valerie R ^a   de Bruyn, Marco ^a   Wei, Yunwei ^a,b   van Ginkel, Robert J ^a   Hirashima, Mitsuomi ^c,d   Niki, Toshiro ^c,d   Nishi, Nozomu ^c   Zhou, Jin ^e   Pouwels, Simon D ^a   Samplonius, Douwe F ^a   Nijman, Hans W ^a   Eggleton, Paul ^f   Helfrich, Wijn ^a,e   Bremer, Edwin ^a,f  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^c KAGAWA UNIVERSITY   (Japan)

^d Research Division GalPharma Company Ltd NEXT   (Japan)

^e HARBIN MEDICAL UNIVERSITY   (China)

^f UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

Author keywords

Autophagy; Colon cancer; Galectin 9; KRAS mutation; Lysosomes

Indexed keywords

CLATHRIN; CYTOTOXIC AGENT; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PROTEIN KINASE C; RECOMBINANT GALECTIN 9; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GALECTIN; KRAS PROTEIN, HUMAN; LGALS9 PROTEIN, HUMAN; PROTEIN P21;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CANCER CELL; CARCINOMA CELL; CELL POLARITY; CELL SWELLING; CELL VACUOLE; CELL VIABILITY ASSAY; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; ENDOCYTOSIS; ENDOSOME; GENE MUTATION; HUMAN; HUMAN CELL; INTERNALIZATION; LYSOSOME; MALE; MOUSE; NONHUMAN; PROTO ONCOGENE; ANIMAL; CACO-2 CELL LINE; CANCER TRANSPLANTATION; CELL SURVIVAL; CHEMISTRY; COLONIC NEOPLASMS; EPITHELIUM; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; METABOLISM; MUTATION; ONCOGENE RAS; PHAGOSOME; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; AUTOPHAGY; CACO-2 CELLS; CELL LINE, TUMOR; CELL SURVIVAL; CLATHRIN; COLONIC NEOPLASMS; EPITHELIUM; GALECTINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; LYSOSOMES; MALE; MICE; MICROSCOPY, FLUORESCENCE; MUTATION; NEOPLASM TRANSPLANTATION; PHAGOSOMES; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 84941968109     PISSN: 15548627     EISSN: 15548635     Source Type: Journal    
DOI: 10.1080/15548627.2015.1063767     Document Type: Article

References (53)

1. Phipps AI, Buchanan DD, Makar KW, Win AK, Baron JA, Lindor NM, Potter JD, Newcomb PA. KRASmutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. Br J Cancer 2013; 108: 1757-64; PMID: 23511557; http://dx. doi. org/10. 1038/bjc. 2013. 118.
2. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486: 532-6; PMID: 22722830.
3. Charette N, Vandeputte C, Starkel P. Ras in digestive oncology: from molecular biology to clinical implications. Curr Opin Oncol 2014; 26: 454-61; PMID: 24849046; http://dx. doi. org/10. 1097/CCO. 0000000000000088.
4. Grothey A, Van CE, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 303-12; PMID: 23177514; http://dx. doi. org/10. 1016/S0140-6736(12)61900-X.
5. Magudia K, Lahoz A, Hall A. K-Ras and B-Raf oncogenes inhibit colon epithelial polarity establishment through up-regulation of c-myc. J Cell Biol 2012; 198: 185-94; PMID: 22826122; http://dx. doi. org/10. 1083/jcb. 201202108.
6. Mosesson Y, Mills GB, Yarden Y. Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer 2008; 8: 835-50; PMID: 18948996; http://dx. doi. org/10. 1038/nrc2521.
7. Martin-Belmonte F, Perez-Moreno M. Epithelial cell polarity, stem cells and cancer. Nat Rev Cancer 2012; 12: 23-38; PMID: NOT_FOUND.
8. Schneider D, Greb C, Koch A, Straube T, Elli A, Delacour D, Jacob R. Trafficking of galectin-3 through endosomal organelles of polarized and non-polarized cells. Eur J Cell Biol 2010; 89: 788-98; PMID: 20705359; http://dx. doi. org/10. 1016/j. ejcb. 2010. 07. 001.
9. Straube T, von MT, Honig E, Greb C, Schneider D, Jacob R. pH-dependent recycling of galectin-3 at the apical membrane of epithelial cells. Traffic 2013; 14: 1014-27; PMID: 23710780; http://dx. doi. org/10. 1111/tra. 12086.
10. Lakshminarayan R, Wunder C, Becken U, Howes MT, Benzing C, Arumugam S, Sales S, Ariotti N, Chambon V, Lamaze C et al. Galectin-3 drives glycosphingolipid-dependent biogenesis of clathrinindependent carriers. Nat Cell Biol 2014; 16: 595-606; PMID: 24837829; http://dx. doi. org/10. 1038/ncb2970.
11. Thurston TLM, Wandel MP, von Muhlinen N, Foeglein A, Randow F. Galectin 8 targets damaged vesicles for autophagy to defend cells against bacterial invasion. Nature 2012; 482: 414-8; PMID: 22246324; http://dx. doi. org/10. 1038/nature10744.
12. Mishra R, Grzybek M, Niki T, Hirashima M, Simons K. Galectin-9 trafficking regulates apical-basal polarity in Madin-Darby canine kidney epithelial cells. Proc Natl Acad Sci U S A 2010; 107: 17633-8; PMID: 20861448; http://dx. doi. org/10. 1073/pnas. 1012424107.
13. Mo D, Costa SA, Ihrke G, Youker RT, Pastor-Soler N, Hughey RP, Weisz OA. Sialylation of N-linked glycans mediates apical delivery of endolyn in MDCK cells via a galectin-9-dependent mechanism. Mol Biol Cell 2012; 23: 3636-46; PMID: 22855528; http://dx. doi. org/10. 1091/mbc. E12-04-0329.
14. Wiersma VR, de BM, Helfrich W, Bremer E. Therapeutic potential of Galectin-9 in human disease. Med Res Rev 2013; 33 Suppl 1: E102-26; PMID: 21793015; http://dx. doi. org/10. 1002/med. 20249.
15. Irie A, Yamauchi A, Kontani K, Kihara M, Liu D, Shirato Y, Seki M, Nishi N, Nakamura T, Yokomise H et al. Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin Cancer Res 2005; 11: 2962-8; PMID: 15837748; http://dx. doi. org/10. 1158/1078-0432. CCR-04-0861.
16. Kageshita T, Kashio Y, Yamauchi A, Seki M, Abedin MJ, Nishi N, Shoji H, Nakamura T, Ono T, Hirashima M. Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. Int J Cancer 2002; 99: 809-16; PMID: 12115481; http://dx. doi. org/10. 1002/ijc. 10436.
17. Liang M, Ueno M, Oomizu S, Arikawa T, Shinonaga R, Zhang S, Yamauchi A, Hirashima M. Galectin-9 expression links to malignant potential of cervical squamous cell carcinoma. J Cancer Res Clin Oncol 2008; 134: 899-907; PMID: 18264727; http://dx. doi. org/10. 1007/s00432-008-0352-z.
18. Yamauchi A, Kontani K, Kihara M, Nishi N, Yokomise H, Hirashima M. Galectin-9, a novel prognostic factor with antimetastatic potential in breast cancer. Breast J 2006; 12: S196-S200; PMID: 16959001; http://dx. doi. org/10. 1111/j. 1075-122X. 2006. 00334. x.
19. Nobumoto A, Nagahara K, Oomizu S, Katoh S, Nishi N, Takeshita K, Niki T, Tominaga A, Yamauchi A, Hirashima M. Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices. Glycobiology 2008; 18: 735-44; PMID: 18579572; http://dx. doi. org/10. 1093/glycob/cwn062.
20. Nishi N, Itoh A, Fujiyama A, Yoshida N, Araya S, Hirashima M, Shoji H, Nakamura T. Development of highly stable galectins: truncation of the linker peptide confers protease-resistance on tandem-repeat type galectins. FEBS Lett 2005; 579: 2058-64; PMID: 15811318; http://dx. doi. org/10. 1016/j. febslet. 2005. 02. 054.
21. Blasco RB, Francoz S, Santamaria D, Canamero M, Dubus P, Charron J, Baccarini M, Barbacid M. c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell 2011; 19: 652-63; PMID: 21514245; http://dx. doi. org/10. 1016/j. ccr. 2011. 04. 002.
22. Karreth FA, Frese KK, DeNicola GM, Baccarini M, Tuveson DA. C-Raf is required for the initiation of lung cancer by K-Ras(G12D). Cancer Discov 2011; 1: 128-36; PMID: 22043453; http://dx. doi. org/10. 1158/2159-8290. CD-10-0044.
23. Wiersma VR, de Bruyn M, van Ginkel RJ, Sigar E, Hirashima M, Niki T, Nishi N, Samplonius DF, Helfrich W, Bremer E. The glycan-binding protein galectin-9 has direct apoptotic activity toward melanoma cells. J Invest Dermatol 2012; 132: 2302-5; PMID: 22572821; http://dx. doi. org/10. 1038/jid. 2012. 133.
24. Guo JY, Chen HY, Mathew R, Fan J, Strohecker AM, Karsli-Uzunbas G, Kamphorst JJ, Chen G, Lemons JM, Karantza V et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev 2011; 25: 460-70; PMID: 21317241; http://dx. doi. org/10. 1101/gad. 2016311.
25. Kim MJ, Woo SJ, Yoon CH, Lee JS, An S, Choi YH, Hwang SG, Yoon G, Lee SJ. Involvement of autophagy in oncogenic K-Ras-induced malignant cell transformation. J Biol Chem 2011; 286: 12924-32; PMID: 21300795; http://dx. doi. org/10. 1074/jbc. M110. 138958.
26. Yoon YH, Cho KS, Hwang JJ, Lee SJ, Choi JA, Koh JY. Induction of lysosomal dilatation, arrested autophagy, and cell death by chloroquine in cultured ARPE-19 cells. Invest Ophthalmol Vis Sci 2010; 51: 6030-7; PMID: 20574031; http://dx. doi. org/10. 1167/iovs. 10-5278.
27. Fehrenbacher N, Bastholm L, Kirkegaard-Sørensen T, Rafn B, Bøttzauw T, Nielsen C, Weber E, Shirasawa S, Kallunki T, J Jäättelä M. Sensitization to the Lysosomal Cell Death Pathway by Oncogene-Induced Down-regulation of Lysosome-Associated Membrane Proteins 1 and 2. Cancer Res 2008; 68: 6623-33; PMID: 18701486; http://dx. doi. org/10. 1158/0008-5472. CAN-08-0463.
28. Lock R, Roy S, Kenific CM, Su JS, Salas E, Ronen SM, Debnath J. Autophagy facilitates glycolysis during Rasmediated oncogenic transformation. Mol Biol Cell 2011; 22: 165-78; PMID: 21119005; http://dx. doi. org/10. 1091/mbc. E10-06-0500.
29. Strohecker AM, White E. Autophagy promotes BrafV600E-driven lung tumorigenesis by preserving mitochondrial metabolism. Autophagy 2014; 10: 384-5; PMID: 24362353; http://dx. doi. org/10. 4161/auto. 27320.
30. Strohecker AM, Guo JY, Karsli-Uzunbas G, Price SM, Chen GJ, Mathew R, McMahon M, White E. Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors. Cancer Discov 2013; 3: 1272-85; PMID: 23965987; http://dx. doi. org/10. 1158/2159-8290. CD-13-0397.
31. Maddodi N, Huang W, Havighurst T, Kim K, Longley BJ, Setaluri V. Induction of autophagy and inhibition of melanoma growth in vitro and in vivo by hyperactivation of oncogenic BRAF. J Invest Dermatol 2010; 130: 1657-67; PMID: 20182446; http://dx. doi. org/10. 1038/jid. 2010. 26.
32. Mancias JD, Kimmelman AC. Targeting autophagy addiction in cancer. Oncotarget 2011; 2: 1302-6; PMID: 22185891.
33. Morgan MJ, Gamez G, Menke C, Hernandez A, Thorburn J, Gidan F, Staskiewicz L, Morgan S, Cummings C, Maycotte P et al. Regulation of autophagy and chloroquine sensitivity by oncogenic RAS in vitro is context-dependent. Autophagy 2014; 10: 1814-26; PMID: 25136801; http://dx. doi. org/10. 4161/auto. 32135.
34. Chen S, Rehman SK, Zhang W, Wen A, Yao L, Zhang J. Autophagy is a therapeutic target in anticancer drug resistance. Biochim Biophys Acta 2010; 1806: 220-9; PMID: 20637264.
35. Lai K, Killingsworth MC, Lee CS. The significance of autophagy in colorectal cancer pathogenesis and implications for therapy. J Clin Pathol 2014; 67: 854-8; PMID: 25055793; http://dx. doi. org/10. 1136/jclinpath-2014-202529.
36. Wei MF, Chen MW, Chen KC, Lou PJ, Lin SY, Hung SC, Hsiao M, Yao CJ, Shieh MJ. Autophagy promotes resistance to photodynamic therapy-induced apoptosis selectively in colorectal cancer stem-like cells. Autophagy 2014; 10: 1179-92; PMID: 24905352; http://dx. doi. org/10. 4161/auto. 28679.
37. Leisching G, Loos B, Botha M, Engelbrecht AM. A nontoxic concentration of Cisplatin induces autophagy in cervical cancer: selective cancer cell death with autophagy inhibition as an adjuvant treatment. Int J Gynecol Cancer 2015; 25: 380-388; PMID: 25695544; http://dx. doi. org/10. 1097/IGC. 0000000000000365.
38. Liao X, Morikawa T, Lochhead P, Imamura Y, Kuchiba A, Yamauchi M, Nosho K, Qian ZR, Nishihara R, Meyerhardt JA et al. Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review. Clin Cancer Res 2012; 18: 2257-68; PMID: 22357840; http://dx. doi. org/10. 1158/1078-0432. CCR-11-2410.
39. Barault L, Veyrie N, Jooste V, Lecorre D, Chapusot C, Ferraz JM, LiC¿vre A, Cortet M, Bouvier AM, Rat P et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a populationbased series of colon cancers. Int J Cancer 2008; 122: 2255-9; PMID: 18224685; http://dx. doi. org/10. 1002/ijc. 23388.
40. Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 2005; 5: 526-42; PMID: 16069816; http://dx. doi. org/10. 1038/nrc1649.
41. Nagae M, Nishi N, Nakamura-Tsuruta S, Hirabayashi J, Wakatsuki S, Kato R. Structural analysis of the human galectin-9 N-terminal carbohydrate recognition domain reveals unexpected properties that differ from the mouse orthologue. J Mol Biol 2008; 375: 119-35; PMID: 18005988; http://dx. doi. org/10. 1016/j. jmb. 2007. 09. 060.
42. Ono K, Hattori H, Uemura K, Nakayama J, Ota H, Katsuyama T. Expression of Forssman antigen in human large intestine. J Histochem Cytochem 1994; 42: 659-65; PMID: 7512587; http://dx. doi. org/10. 1177/42. 5. 7512587.
43. Hakomori S. Tumor-associated carbohydrate antigens. Annu Rev Immunol 1984; 2: 103-26; PMID: 6085749; http://dx. doi. org/10. 1146/annurev. iy. 02. 040184. 000535.
44. Preto A, Figueiredo J, Velho S, Ribeiro AS, Soares P, Oliveira C, Seruca R. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations. J Pathol 2008; 214: 320-7; PMID: 18098337; http://dx. doi. org/10. 1002/path. 2295.
45. Kim JS, Lee C, Foxworth A, Waldman T. B-Raf is dispensable for K-Ras-mediated oncogenesis in human cancer cells. Cancer Res 2004; 64: 1932-7; PMID: 15026326; http://dx. doi. org/10. 1158/0008-5472. CAN-03-3862.
46. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418: 934-4; PMID: 12198537; http://dx. doi. org/10. 1038/418934a.
47. Freeman AK, Ritt DA, Morrison DK. The importance of Raf dimerization in cell signaling. Small GTPases 2013; 4: 180-5; PMID: 23985533; http://dx. doi. org/10. 4161/sgtp. 26117.
48. Freeman AK, Ritt DA, Morrison DK. Effects of Raf Dimerization and Its Inhibition on Normal and Disease-Associated Raf Signaling. Mol Cell 2013; 49: 751-8; PMID: 23352452; http://dx. doi. org/10. 1016/j. molcel. 2012. 12. 018.
49. Lavoie H, Thevakumaran N, Gavory G, Li JJ, Padeganeh A, Guiral S, Duchaine J, Mao DY, Bouvier M, Sicheri F et al. Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization. Nat Chem Biol 2013; 9: 428-36; PMID: 23685672; http://dx. doi. org/10. 1038/nchembio. 1257.
50. Nobumoto A, Oomizu S, Arikawa T, Katoh S, Nagahara K, Miyake M, Nishi N, Takeshita K, Niki T, Yamauchi A et al. Galectin-9 expands unique macrophages exhibiting plasmacytoid dendritic cell-like phenotypes that activate NK cells in tumor-bearing mice. Clin Immunol 2009; 130: 322-30; PMID: 18974023; http://dx. doi. org/10. 1016/j. clim. 2008. 09. 014.
51. Nagahara K, Arikawa T, Oomizu S, Kontani K, Nobumoto A, Tateno H, Watanabe K, Niki T, Katoh S, Miyake M et al. Galectin-9 increases Tim-3C dendritic cells and CD8C T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. J Immunol 2008; 181: 7660-9; PMID: 19017954; http://dx. doi. org/10. 4049/jimmunol. 181. 11. 7660.
52. Gooden MJ, Wiersma VR, Samplonius DF, Gerssen J, van Ginkel RJ, Nijman HW, Hirashima M, Niki T, Eggleton P, Helfrich W et al. Galectin-9 activates and expands human T-helper 1 cells. PLoS One 2013; 8: e65616-; PMID: 23741502; http://dx. doi. org/10. 1371/journal. pone. 0065616.
53. Klibi J, Niki T, Riedel A, Pioche-Durieu C, Souquere S, Rubinstein E, Le MS, Guigay J, Hirashima M, Guemira F et al. Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. Blood 2009; 113: 1957-66; PMID: 19005181; http://dx. doi. org/10. 1182/blood-2008-02-142596.